Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALC 
Alcon AG (ALC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ALC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 16.45% | Avg. Invested days 50 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 46.06B USD | Price to earnings Ratio 45.22 | 1Y Target Price 106.56 |
Price to earnings Ratio 45.22 | 1Y Target Price 106.56 | ||
Volume (30-day avg) 1612878 | Beta 0.83 | 52 Weeks Range 77.29 - 101.10 | Updated Date 04/2/2025 |
52 Weeks Range 77.29 - 101.10 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 0.29% | Basic EPS (TTM) 2.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.27% | Operating Margin (TTM) 13.63% |
Management Effectiveness
Return on Assets (TTM) 2.85% | Return on Equity (TTM) 4.83% |
Valuation
Trailing PE 45.22 | Forward PE 29.5 | Enterprise Value 50028297686 | Price to Sales(TTM) 4.65 |
Enterprise Value 50028297686 | Price to Sales(TTM) 4.65 | ||
Enterprise Value to Revenue 5.05 | Enterprise Value to EBITDA 18.7 | Shares Outstanding 494616000 | Shares Floating 493513330 |
Shares Outstanding 494616000 | Shares Floating 493513330 | ||
Percent Insiders 0.13 | Percent Institutions 74.79 |
Analyst Ratings
Rating 4.44 | Target Price 100.1 | Buy 6 | Strong Buy 17 |
Buy 6 | Strong Buy 17 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alcon AG
Company Overview
History and Background
Alcon was founded in 1945 as a pharmacy in Fort Worth, Texas. In 1977, it was acquired by Nestlu00e9. Novartis acquired Alcon from Nestlu00e9 in stages between 2008 and 2011 and in 2019, Alcon was spun off as an independent publicly traded company. Alcon is now headquartered in Geneva, Switzerland.
Core Business Areas
- Surgical: Offers a broad portfolio of products for cataract, refractive, vitreoretinal surgery, and advanced technology intraocular lenses (IOLs) to address refractive error.
- Vision Care: Provides a wide range of contact lenses and lens care products, addressing various vision correction needs.
Leadership and Structure
David Endicott serves as the Chief Executive Officer. The company operates with a global structure, with regional headquarters and a board of directors overseeing operations.
Top Products and Market Share
Key Offerings
- Product Name 1: Dailies Total1: Daily disposable contact lenses known for their high oxygen transmissibility and comfort. Alcon held the largest share of the global contact lens market in 2023 at approximately 33%. Competitors include Johnson & Johnson (JNJ), CooperCompanies (COO), and Bausch + Lomb (BLCO).
- Product Name 2: Clarity Family of Contact Lenses: Spherical, toric, and multifocal contact lenses made with silicone hydrogel. Competitors include Johnson & Johnson (JNJ), CooperCompanies (COO), and Bausch + Lomb (BLCO).
- Product Name 3: Centurion Vision System: A phacoemulsification system used in cataract surgery. Competitors include Johnson & Johnson (JNJ), and Bausch + Lomb (BLCO).
Market Dynamics
Industry Overview
The eye care industry is driven by an aging global population, increasing prevalence of eye diseases (like cataracts and glaucoma), and growing demand for vision correction solutions. Technological advancements are also playing a key role.
Positioning
Alcon is a leading player in the global eye care market, with a strong position in both the surgical and vision care segments. Its competitive advantages include a broad product portfolio, strong brand recognition, and a global distribution network.
Total Addressable Market (TAM)
The global eye care market is estimated to be ~$50 billion. Alcon is positioned to capture a significant portion of this TAM through its diversified product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diversified product portfolio
- Global distribution network
- Leading position in key market segments
- Innovative product pipeline
Weaknesses
- Dependence on certain key products
- Exposure to regulatory risks
- Competition from established and emerging players
- Price sensitivity in some markets
Opportunities
- Expanding into emerging markets
- Developing new and innovative products
- Acquiring complementary businesses
- Increasing adoption of advanced technologies
- Growing demand for premium IOLs and contact lenses
Threats
- Increased competition
- Pricing pressures
- Regulatory changes
- Economic downturns
- Technological disruption
Competitors and Market Share
Key Competitors
- JNJ
- COO
- BLCO
Competitive Landscape
Alcon possesses a wide range of product portfolio and good brand reputation. On the other hand, its competitiors also make innovative product. Also, there are multiple regulatory risks that each face.
Major Acquisitions
Ivantis, Inc.
- Year: 2022
- Acquisition Price (USD millions): 475
- Strategic Rationale: Expanded Alcon's glaucoma surgical portfolio with the Hydrus Microstent.
Growth Trajectory and Initiatives
Historical Growth: Historical growth information requires specific financial data which cannot be accessed at this moment. Therefore, information is unavailable.
Future Projections: Future projections require specific financial data which cannot be accessed at this moment. Therefore, information is unavailable.
Recent Initiatives: Alcon is focused on innovation and expanding its product offerings, particularly in the surgical and vision care segments. Recent initiatives include new product launches, strategic partnerships, and investments in research and development.
Summary
Alcon is a leading eye care company with strong market positions and a diverse product portfolio. Its strengths include a global presence, innovative pipeline and the vision care sector. Potential weaknesses stem from external factors like competition and regulatory pressures. Alcon needs to continue to invest in research and development to maintain its competitive advantage.
Similar Companies
BLCO
Bausch + Lomb Corp
BLCO
Bausch + Lomb Corp
COO
The Cooper Companies, Inc. Common Stock
COO
The Cooper Companies, Inc. Common Stock
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Actual results may vary. Market share data can vary among different reporting agencies. Financial data based on estimates and publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alcon AG
Exchange NYSE | Headquaters - | ||
IPO Launch date 2019-04-09 | CEO & Director Mr. David J. Endicott | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 25599 | Website https://www.alcon.com |
Full time employees 25599 | Website https://www.alcon.com | ||
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.